OpenEvidence: The AI Every Clinician Needs for Instant, Evidence-Based Decisions
What is OpenEvidence? OpenEvidence is an AI-powered medical search and clinical decision-support platform that lets verified clinicians ask natural-language questions and receive evidence-synthesised, referenced answers at the point of care. The product combines a large indexed corpus of peer-reviewed literature and publisher content (including NEJM and JAMA partnerships) with AI summarisation, rapid literature retrieval, and […]
Feature Categories
What is OpenEvidence?
OpenEvidence is an AI-powered medical search and clinical decision-support platform that lets verified clinicians ask natural-language questions and receive evidence-synthesised, referenced answers at the point of care. The product combines a large indexed corpus of peer-reviewed literature and publisher content (including NEJM and JAMA partnerships) with AI summarisation, rapid literature retrieval, and clinician-facing UX (web + mobile).
Recent features (e.g., Visits) extend capabilities into the patient encounter—providing real-time evidence, transcription, and draft clinical notes while preserving citation provenance. OpenEvidence is positioned for clinicians, health systems, and researchers who need fast, evidence-grounded answers to clinical questions.
It's been hailed as the ChatGPT for verified Doctors.
Why Leading Healthcare Teams Trust OpenEvidence
-
OpenEvidence is widely trusted, serving over 40% of physicians in the U.S. and used in more than 10,000 hospitals. It is the fastest-growing healthcare AI platform in history, with a 2,000%+ year-over-year growth rate.
-
The platform aggregates and synthesises trusted, peer-reviewed medical evidence from top sources such as The New England Journal of Medicine, JAMA, and other specialty journals. It provides evidence-based answers that are grounded in the latest clinical research, ensuring clinical reliability and accuracy.
-
OpenEvidence is HIPAA-compliant, with strong security protocols including encryption for data at rest and in transit. It undergoes continuous security testing, including annual penetration tests and vulnerability scans, to maintain compliance and safeguard protected health information (PHI).
-
The company has raised over $300 million in funding, with notable investors like Google Ventures, Kleiner Perkins, and Sequoia Capital, reflecting strong market confidence and stability.
-
OpenEvidence was founded by Daniel Nadler, a proven serial entrepreneur, with a strategic focus on combining AI with rigorous medical validation, supported by a world-class medical advisory board to ensure ethical standards and clinical relevance.
-
The AI has achieved significant recognition by being the first AI ever to score a perfect 100% on the United States Medical Licensing Examination (USMLE), highlighting its advanced medical knowledge capabilities.
-
The platform operates with ethical rigor by providing transparent, evidence-based answers without hallucinations, meaning if evidence is inconclusive, it simply refrains from giving an answer to avoid misinformation.
-
OpenEvidence offers its core product for free to physicians, facilitating broad access and democratization of cutting-edge medical knowledge across diverse healthcare settings, including underserved communities.
-
There are no public records of recent mergers or acquisitions involving OpenEvidence; however, the company's rapid growth and strategic partnerships with leading medical publishers position it strongly in the healthcare AI space.
Top 3 Pain Points OpenEvidence Fixes in Healthcare
| Problem | How OpenEvidence Solves It |
|---|---|
| 1. Information overload from vast medical literature | Uses AI to rapidly search, filter, and summarize peer-reviewed studies into concise, evidence-based answers |
| 2. Time pressure in clinical decision-making | Provides instant, referenced insights at the point of care through web and mobile platforms |
| 3. Difficulty maintaining up-to-date knowledge | Continuously ingests and analyzes new medical publications, keeping clinicians current with the latest evidence |
Feature Category Summary: OpenEvidence
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | OpenEvidence terms and BAAs (per public summaries) frame it as an AI‑enabled clinical reference and decision‑support tool, clarifying that it provides educational support and is not a diagnostic engine, but there is no indication that the platform itself is validated as a 21 CFR Part 11/Annex 11/GxP system with formal computerized‑system validation or audit‑trail controls for regulatory inspections. No public documentation found that explicitly markets OpenEvidence as regulatory‑ready for FDA/EMA GxP contexts. | NA |
| Clinical Trial Support | Available descriptions and studies focus on supporting frontline clinical decision‑making and evidence retrieval (guidelines, RCTs, systematic reviews) for practicing clinicians; there is no description of features for protocol design, trial recruitment, monitoring, or regulatory submission management. No public documentation found that OpenEvidence functions as a CTMS/EDC or dedicated clinical‑trial support platform. | NA |
| Supply Chain & Quality | The tool operates on published literature and guidelines to generate evidence‑based answers; there is no mention of pharmaceutical manufacturing systems, batch QA, serialization, or counterfeit‑detection workflows. No public documentation found for supply‑chain or manufacturing‑quality capabilities. | NA |
| Efficiency & Cost-Saving | Physician‑facing materials emphasize that OpenEvidence “saves time for physicians” by surfacing guideline‑concordant recommendations and the supporting evidence base directly, instead of manual PubMed or guideline searches, and that it helps clinicians make faster evidence‑based decisions at the point of care. While cost reductions are not quantified in currency, explicit claims of time savings and workflow streamlining for clinicians satisfy the efficiency and cost‑saving criterion. | YES |
| Scalable / Enterprise-Grade | OpenEvidence has secured large venture funding (e.g., a US$210m Series B) and has announced a collaboration with the American College of Cardiology to “advance AI‑enabled guideline‑based care,” indicating planned or ongoing deployment across large professional networks. However, public sources do not yet provide concrete evidence of multi‑site hospital system roll‑outs or enterprise contracts with large pharma/biotech organisations, so enterprise‑grade use in that specific domain cannot be confirmed. | NA |
| HIPAA Compliant | Multiple clinician posts and announcements state that OpenEvidence is now HIPAA compliant and offers a HIPAA‑compliant Business Associate Agreement (BAA), allowing U.S. covered entities to create, receive, store, or transmit PHI under specified safeguards. The guidance clarifies that, under the BAA and updated Terms of Use, PHI can be entered in accordance with HIPAA privacy and security standards, and users are advised to de‑identify data unless the BAA is in place, which is explicit evidence of HIPAA‑aligned operation. | YES |
| Clinically Validated | A peer‑reviewed retrospective study of five real primary‑care cases found that OpenEvidence provided accurate, evidence‑based recommendations that aligned with physician clinical decisions in chronic disease management and was rated highly on clarity, relevance, and evidence support, though it primarily reinforced rather than altered decisions. The authors conclude that OpenEvidence performs comparably to physician CDM in these scenarios and recommend prospective trials to assess outcomes, providing initial clinical validation evidence for its intended use as an adjunct clinical decision‑support tool. | YES |
| EHR Integration | Public materials and evaluations describe OpenEvidence as a web‑based and mobile clinical assistant used alongside, rather than embedded within, EHRs; there is no documentation of SMART‑on‑FHIR, HL7, or named EHR integrations (e.g., Epic, Cerner) in the sources reviewed. No public documentation found that evidences direct EHR or clinical‑system integration. | NA |
| Explainable AI | By design, OpenEvidence surfaces guideline‑based and evidence‑based recommendations together with direct citations and links to primary literature (RCTs, meta‑analyses, guidelines), and physicians in the validation study specifically rated the tool’s evidence support and cited materials as accurate. This citation‑centric design provides transparent traceability from recommendations to underlying evidence and is explicit evidence of explainability in its AI‑generated insights. | YES |
| Real-Time Analytics | OpenEvidence operates as an on‑demand clinical assistant: clinicians pose questions about real cases and receive evidence‑based recommendations and literature citations within a single interaction, supporting point‑of‑care decision‑making. This synchronous, per‑query evidence synthesis constitutes real‑time analytics for clinical decision support, even though it does not process continuous data streams. | YES |
| Bias Detection | None of the reviewed articles, validation studies, or product communications describe explicit bias‑detection or fairness‑monitoring capabilities (e.g., performance stratified by demographics, automatic detection of biased recommendations, or fairness metrics for the underlying models). No public documentation found for algorithmic bias‑detection or mitigation features. | NA |
| Ethical Safeguards | OpenEvidence’s Terms/BAA guidance (as summarized for clinicians) specifies safe‑use constraints: the tool is advisory and not a diagnostic engine, clinicians must retain judgment and follow local standards, PHI use is governed by minimum‑necessary principles and BAAs, and the vendor commits to breach notification and privacy protections. These stipulations and governance requirements, combined with positioning as decision support rather than order entry, constitute built‑in ethical safeguards and human‑in‑the‑loop use‑case restrictions. | YES |
Risks & Limitations: OpenEvidence
-
Extraction & nuance limits: automated NLP performs best on structured abstracts and well-reported RCTs—complex observational designs, subgroup effect extraction, and poorly reported outcomes still require substantial expert review.
-
Bias & coverage: literature ingestion quality depends on source selection and access (paywalled journals, grey literature); sampling and manual checks are needed to ensure comprehensive coverage.
-
Regulatory acceptance: automated outputs accelerate drafting, but regulatory submissions still require human methodological oversight and signed accountability. Plan for validation logs and human QC steps.
-
Customisation effort: speciality ontologies, outcome harmonisation and bespoke GRADE rules require initial configuration—budget time and PS for high-complexity topics.
Share This AI Tool
Get a neutral, no obligation view of whether this AI tool fits your portfolio
